ITMCTR2100004310招募中1 期
A multicenter randomized double-blind parallel controlled trial of chuangui clearing damp mixture in the treatment of primary hyperuricemia
Affiliated Hospital of Qingdao University0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 75（—）
- 性别
- All
入选标准
- •(1) Regular residents of Huangshan Village, Laoshan District, Qingdao City and Beizhai Health Center, Qingdao City, Shandong Province, and outpatients or inpatients of the endocrinology department of the Affiliated Hospital of Qingdao University and Rizhao People's Hospital, aged between 18 and 75 years old, diagnosed with hyperuricemia and meeting the standard of TCM syndrome differentiation of humidity and turbidities;
- •(2) Patients with non-acute gout;
- •(3) Patients who signed the informed consent to take the medication as required by the study protocol and were evaluated.
排除标准
- •(1) secondary gout has been clearly diagnosed;
- •(2) You are taking drugs for blood uric acid metabolism, such as dihydroclorazide, furosemide, diuric acid, pyrazinamide, low-dose aspirin, etc., as well as drugs containing the above-mentioned ingredients, such as compound antihypertensive tablets;Or had taken glucocorticoids within 1 month before enrollment;Or use of nonsteroidal anti-inflammatory drugs or other pain medications within 48 hours prior to baseline evaluation;
- •(3) patients with xanthuria;
- •(4) Joint diseases caused by rheumatoid arthritis requiring treatment or other reasons;
- •(5) with severe cardiovascular diseases (such as: decompensated heart failure (NYHA ? and IV);Unstable angina pectoris;A history of myocardial infarction within the previous 12 months), heart failure, tumor activity, immunodeficiency, or severe infection
- •(6) Patients with active liver disease or cirrhosis, or abnormal liver function, with serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) exceeding 1.5 times the upper limit of the normal range;
- •(7) The serum creatinine (Cr) exceeds the upper limit of the reference range;
- •(8) patients with late deformity, disability or loss of working ability;
- •(9) Patients with active gastrointestinal ulcer or taking anti-ulcer drugs;
- •(10) People with brain diseases, abnormal judgment, mental or legal disabilities
- •(11) Suspected or confirmed history of alcohol or drug abuse, or other diseases that, according to the investigator's judgment, reduce the possibility of inclusion or complicate inclusion, such as frequent changes in the work environment, which may easily cause loss of follow-up;
- •(12) Women who are pregnant, lactating or have a recent birth plan;
- •(13) People who are known to be allergic to the ingredients of this drug;
- •(14) Candidates who have participated in or are participating in the clinical trial within the last 3 months, or whom the investigator considers unsuitable for the clinical trial for other reasons.
研究者
相似试验
尚未招募
不适用
A multicenter randomized, double-blind, parallel controlled, trial for integrated traditional Chinese medicine and western short-course chemotherapy in the treatment of multidrug resistance pulmonary tubPulmonary tuberculosisITMCTR1900002779onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
尚未招募
3 期
Phase III clinical study evaluates the efficacy and safety of a combination eye drop containing Moxifloxacin/Nepafenac compared to Moxifloxacin/Ketorolac for patients with Inflammatory Ocular ConditionsCTRI/2024/08/071785Akums Drugs & Pharmaceuticals Limited
已完成
3 期
A multicentric randomized comparative phase III clinical study of FDC of Azelnidipine 16 mg plus Telmisartan 40 mg Film Coated Tablets Versus FDC of Amlodipine 5 mg plus Telmisartan 40 mg tablets in subjects with stage 2 hypertensioCTRI/2022/07/044031Mascot Health Series PVT Ltd220
已完成
不适用
Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone-E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119PER-117-06OVARTIS BIOSCIENSES PERU S.A.,
已完成
不适用
.A.PER-007-98MERCK SHARP & DOHME PERU S.R.L.,